Back to Search
Start Over
Intravenous ferric carboxymaltose does not provide benefits in reperfused acute myocardial infarction in the rat with normal iron status.
- Source :
-
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2021 Sep; Vol. 141, pp. 111893. Date of Electronic Publication: 2021 Jul 06. - Publication Year :
- 2021
-
Abstract
- Background: Iron deficiency has been implicated in the pathophysiology of heart failure and myocardial ischemia and reperfusion injury. Moreover, reperfused heart seems to lose iron, thus even subjects with normal iron status could benefit from iron therapy. Impaired mitochondrial respiration and energy starvation may be among possible consequences of myocardial iron deficiency. So far no attempts have been made to treat acute coronary syndromes with iron. Thus our aim was to verify the hypothesis that intravenous iron therapy given during reperfusion of an acute myocardial infarction will reduce left ventricular remodeling and hemodynamic abnormalities in a 2-month follow-up as well as early mitochondrial dysfunction and mortality, in the rat with normal iron status.<br />Methods and Results: A single dose of ferric carboxymaltose was administered intravenously at 30 min of reperfusion following 30 min of ischemia in the rat model of myocardial infarction. Ventricular arrhythmias were monitored using a telemetric system, activity of mitochondrial enzymes was assessed using spectrophotometry, serum markers of oxidative stress and inflammation were determined and left ventricular function and remodeling were monitored using echocardiography and pressure-volume loops. Intravenous iron therapy did not affect post-myocardial infarction mortality, left ventricular size or function, ventricular arrhythmias, activity of mitochondrial respiratory chain, oxidative stress or markers of inflammation, but was not associated with any adverse effects.<br />Conclusions: Although ferric carboxymaltose given at reperfusion was safe, it was ineffective in this model of reperfused myocardial infarction in the rat with normal iron status.<br /> (Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Subjects :
- Administration, Intravenous
Animals
Arrhythmias, Cardiac drug therapy
Echocardiography
Ferric Compounds administration & dosage
Hemodynamics drug effects
Hypertrophy, Left Ventricular prevention & control
Male
Maltose administration & dosage
Maltose therapeutic use
Mitochondria, Heart drug effects
Mitochondria, Heart metabolism
Myocardial Infarction drug therapy
Myocardial Reperfusion
Myocardial Reperfusion Injury mortality
Oxidative Stress drug effects
Rats
Rats, Wistar
Ventricular Remodeling drug effects
Ferric Compounds therapeutic use
Iron metabolism
Maltose analogs & derivatives
Myocardial Reperfusion Injury drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1950-6007
- Volume :
- 141
- Database :
- MEDLINE
- Journal :
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
- Publication Type :
- Academic Journal
- Accession number :
- 34243097
- Full Text :
- https://doi.org/10.1016/j.biopha.2021.111893